Samuel K. Kulp
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
279
Citations
6,171
Est. group size
~24
Recurring co-author estimate
Active years
35
Publishing since 1992
Samuel K. Kulp's research focuses on cancer cell biology, particularly signaling pathways involved in tumor growth and drug resistance, such as PI3K/AKT/mTOR signaling, and molecular targets like histone deacetylases and hormone receptors. Much of the work involves developing and testing small-molecule inhibitors (for example, celecoxib-derived compounds) aimed at overcoming resistance to existing cancer drugs like EGFR inhibitors and tamoxifen. Note that several publications in this record are retractions or corrections, which prospective students should be aware of when reviewing this body of work.
Publication counts were modest and fairly steady from 2017-2022 (2-7 per year) but show an unusual, large spike in 2023 (73) and 2025 (38), driven substantially by supplementary materials, corrections, and retractions rather than solely new original research articles.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Supplementary Material from From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors
2023
- Data from From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors
2023
- Data from From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors
2023
- Supplementary Material from From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors
2023
- Supplementary Legends 1-3 from Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors
2023
- Supplementary Methods and Materials from Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors
2023
- Supplementary Figures 1-3 from Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors
2023
- Supplementary Figures 1-3 from Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors
2023
- Supplementary Methods and Materials from Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors
2023
- Supplementary Legends 1-3 from Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors
2023
- Data from Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors
2023
- Data from Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors
2023
- Correction: Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells
Oncogenesis · 2020
- Retraction: Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability
Oncotarget · 2020
- Editor's Note: From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors
Cancer Research · 2019
- Carcinogenesis×5
- Regular and Young Investigator Award Abstracts×5
- Clinical Cancer Research×3
- Scientific Reports×3
- Cancer Immunology Research×2
- Larry Beaver
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Daniel Canfield
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Allison Mustonen
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Hannah Phillips
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Steven Sher
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile